Related Experiment Video
Updated: Aug 22, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
1Division of Gastroenterology, Liyuan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430077, Hubei, China.
Abstract:
Cancer is frequently caused by microRNAs, which control post-transcriptional levels of gene expression by binding to target mRNAs. MiR-29a-3p has recently been shown to play a twofold function in the majority of malignancies, including colorectal cancer (CRC), according to mounting evidence. Here, we not only briefly summarize such connection between miR-29a-3p and cancers, but aslo primarily evaluate the miR-29a-3p expression pattern, clinical applicability, and molecular mechanisms in CRC to provide a guide for future studies. This review established the diagnostic and prognostic value of miR-29a-3p abnormalty in a variety of clinical samples for CRC. Furthermore, current molecular mechanisms of miR-29a-3p for regulating cancerous biological processes such growth, invasion, metastasis, the epithelial-mesenchymal transformation process, and immunomodulation through its upstream regulatory factors and downstream targeted genes were briefly explored. More specifically, miR-29a-3p has been linked to a few medications that have been shown to have anticancer benefits. To sum up, miR-29a-3p is a promising biomarker and prospective therapeutic target for the diagnosis and prognosis of CRC, but further research is still needed to establish a theoretical basis for more practical applications.
Insights
MicroRNAs regulate gene expression and are implicated in cancer. MiR-29a-3p shows promise as a biomarker and therapeutic target for colorectal cancer (CRC), with potential diagnostic and prognostic value.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are key regulators of post-transcriptional gene expression.
- Dysregulation of miRNAs is frequently implicated in cancer development.
- MiR-29a-3p has emerged as a significant player in various malignancies, including colorectal cancer (CRC).
Purpose of the Study:
- To review the role of miR-29a-3p in cancer, focusing on its expression, clinical utility, and molecular mechanisms in CRC.
- To evaluate miR-29a-3p as a potential diagnostic and prognostic biomarker for CRC.
- To explore the therapeutic potential of miR-29a-3p in CRC treatment.
Main Methods:
- Literature review and synthesis of existing research on miR-29a-3p in cancer.
- Analysis of miR-29a-3p expression patterns in clinical samples.
- Exploration of molecular mechanisms involving upstream regulators and downstream targets of miR-29a-3p.
- Investigation of the link between miR-29a-3p and anticancer therapeutic agents.
Main Results:
- Abnormal expression of miR-29a-3p is associated with diagnostic and prognostic value in CRC.
- MiR-29a-3p influences critical cancer processes including growth, invasion, metastasis, epithelial-mesenchymal transition, and immunomodulation.
- Specific upstream and downstream molecular players mediating miR-29a-3p's effects in CRC have been identified.
- MiR-29a-3p is linked to several drugs exhibiting anticancer properties.
Conclusions:
- MiR-29a-3p is a promising biomarker for the diagnosis and prognosis of colorectal cancer.
- Targeting miR-29a-3p represents a potential therapeutic strategy for CRC.
- Further research is warranted to translate these findings into clinical applications for CRC management.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
